Go to https://cpicpgx.org/(Links to an external site.) (Links to an external site.)Look up and click on GuidelinesPick a medication associated (there are 24) with a gene disorder and discuss or type i

Go to

https://cpicpgx.org/(Links to an external site.)

(Links to an external site.)

Look up and click on GuidelinesPick a medication associated (there are 24) with a gene disorder and discuss or type in a medication. For example, Allopurinol.

https://cpicpgx.org/content/guideline/publication/allopurinol/2015/26094938.pdf(Links to an external site.)

Example:Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Human Leukocyte Antigen-B Genotype and Allopurinol Dosing: 2015 UpdatePharmacogenetic tests are slowly being integrated into clinical practice. This is partly due to the lack of specific guidelines on how to accurately modify medication dosages based on the genetic test results (Saito et al., 2016). The Clinical Pharmacogenetics Implementation Consortium (CPIC) of the National Institutes of Health’s Pharmacogenomics Research Network and the Pharmacogenomics Knowledge Base (PharmGKB) provide guidelines which help facilitate the translation of pharmacogenomic knowledge from the lab to the bedside (Saito et al., 2016). One set of guidelines that have been developed, pertain to the human leukocyte antigen-B (HLA-B) 58:01* genotype and the drug allopurinol. Allopurinol is the most commonly prescribed medication for the treatment of gout. Allopurinol is also one of the most common causes of severe cutaneous adverse reactions (SCAR). The literature review yielded 26 relevant primary studies showing an association between HLA-B*58:01 and allopurinol SCAR. These SCAR reactions include drug hypersensitivity syndrome, Stevens-Johnson syndrome and toxic epidermal necrolysis. Because of this, individuals with at least one HLA-B*58:01 allele (positive testing), cannot receive allopurinol for the treatment of gout. The 2012 American College of Rheumatology Guidelines for Management of Gout recommends testing for the HLA-B*58:01 allele in selected subpopulations who have an elevated risk for allopurinol hypersensitivity syndrome. Those individuals have been determined to be people of Korean decent with stage 3 or worse chronic kidney disease and people of Han-Chinese or Thai descent (Relling & Klein, 2018).

ReferencesRelling, M.V. & Klein, T.E. (2018). CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clinical Pharmacology & Therapeutics, 89(3), 464 – 467.

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3098762/(Links to an external site.)

Saito, Y., Stamp, L.K., Caudle, K.E., Hershfield, M.S., McDonagh, E.M., Callaghan, J.T., Tassaneeyakul, W., Mushiroda, T., Kamatani, N., Goldspiel, B.R., Phillips, E.J., Klein, T.E., & Lee, M.T. (2016). Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update. Clinical Pharmacology & Therapeutics, 99(1), 36 –37.

https://cpicpgx.org/content/guideline/publication/allopurinol/2015/26094938.pdf(Links to an external site.)

Go to https://cpicpgx.org/(Links to an external site.) (Links to an external site.)Look up and click on GuidelinesPick a medication associated (there are 24) with a gene disorder and discuss or type i
Discussion Rubric Threaded Discussion 4 3 2 1 0 Total Original Post Discussion is 150 words minimum and has logical flow . Body of work is 150 words (minimum) and has logical flow. The original post is less than 150 words and/or does not ha ve logical flow. No post Original Post: Discuss at least 2 key points from the assignment Two key points are discussed One key point is discussed No key points are discussed No key points are discussed. No post Original Post References: Two scholarly, peer -reviewed sources in -text and on reference list. Two s ource are peer -viewed, scholarly, published within the last five years, and no APA errors Two s ource s are peer – viewed, scholarly, published within the last five years, and with 1-2 APA errors One source is peer -viewed, scholarly, published within the last five years, and /or has 3 -4- 2 APA errors No peer – reviewed, scholarly source s, published within the last five years, and / or multiple (more than four) APA errors No post Reply Post : Reply to at least one peer’s original post. Discuss one point you agree with or one point you disagree with and explain why Reply to one peer post is present with agree/disagree point discussed with explanation Reply to one peer post is present, with agree/disagree point discussed, no explanation Reply to one peer post is present, no point is discussed, explanation is lacking Posting is unorganized – no comparison /contrast discussed No post Reply Post: 100 word minimum response and logical flow Reply is 100 words (minimum) and has logical flow. The reply is less than is 100 words (minimum) and /or does not have logical flow. No post Reply Reference: One scholarly, peer -reviewed reference in -text and on reference list in APA format. Source is peer – viewed, scholarly, published within the last five years, and in APA format Peer -reviewed, scholarly source, published within the last five years , and has 1-2 APA errors Peer -reviewed, scholarly , published within the last five years , and has 3 -4 APA errors No peer – reviewed, scholarly source , published within the last five years, and / or multiple (more than four) APA errors No post Additional : Organization errors (difficult to follow, and/or ineffective paragraph structure) Word choice (consistent use of incorrect words) Sentence fluency (run -on sentences, missing words, sentence fragments, and / or ineffective sentence structures) Parts of speech – (subject/verb agreement, tense shifts or inconsistences, errors with prepositions or article usage, and / or incorrect form usage) Conventions (spelling, punctuation, and / or capitalization) There are 0 errors noted 2-3 errors noted 3-4 errors noted 5-6 errors noted 7 or more